A study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.
- Conditions
- Therapeutic area: Diseases [C] - Cancer [C04]MedDRA version: 16.1 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864ON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE
- Registration Number
- EUCTR2013-003331-30-ES
- Lead Sponsor
- Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 1225
?Histologically or cytologically documented locally advanced or metastatic (i.e., Stage IIIB not eligible for definitive chemoradiotherapy, Stage IV, or recurrent) NSCLC
?Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (preferred) or at least 15 unstained slides, with an associated pathology report, for central testing and determined to be evaluable for tumor PD-L1 expression prior to study enrollment
?Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen
?Measurable disease, as defined by RECIST v1.1
?ECOG performance status of 0 or 1
?Life expectancy > 12 weeks
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 750
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 100
?Received therapeutic oral or IV antibiotics within 2 weeks prior to randomization
?Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
?Administration of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live attenuated vaccine will be required during the study
?Positive test for HIV
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The primary objective of this study is to determine if MPDL3280A treatment results in superior OS compared with docetaxel treatment in patients with locally advanced or metastatic NSCLC who have progressed during or following a platinum-containing regimen;<br> Secondary Objective: The secondary efficacy objectives of this study are:<br> - To evaluate the efficacy of MPDL3280A compared with docetaxel with respect to antitumor effects as measured by ORR per investigator using RECIST v1.1<br> - To evaluate the efficacy of MPDL3280A compared with docetaxel with respect to antitumor effects as measured by PFS per investigator using RECIST v1.1<br> ;Primary end point(s): The primary efficacy outcome measure is OS, defined as the time from randomization to death from any cause.;Timepoint(s) of evaluation of this end point: Please refer to section E.5.1
- Secondary Outcome Measures
Name Time Method Secondary end point(s): ?PFS, defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator using RECIST v1.1 criteria, or death from any cause.;Timepoint(s) of evaluation of this end point: Please refer to section E.5.2.